Matrix metalloproteinase-2 (MMP-2) immunoreactive protein - A new prognostic marker in uveal melanoma?

Journal of Pathology

Volumn 188, Issue 1, 1999, Pages 56-62

  Väisänen, Anne ^c   Kallioinen, Matti ^c   Von Dickhoff, Kai ^c   Laatikainen, Leila ^c   Höyhtyä, Matti ^a   Turpeenniemi Hujanen, Taina ^b  

^a Diabor Oy   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

^c NONE

Author keywords

Gelatinases; Metastasis; TIMP; Uveal melanoma

Indexed keywords

GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE;

ADULT; AGE; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORNEA EPITHELIUM; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SEX DIFFERENCE; TUMOR VOLUME; UVEA MELANOMA; ZYMOGRAPHY;

EID: 0345299210     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199905)188:1<56::AID-PATH304>3.3.CO;2-2     Document Type: Article

References (31)

1. Mooy CM, de Jong PTVM. Prognostic parameters in uveal melanoma: a review. Surv Ophthalmol 1996; 41: 215-228.
2. Seregård S, Kock E. Prognostic indicators following enucleation for posterior uveal melanoma. Acta Ophthalmol Scand 1995; 73: 340-344.
3. Stetler-Stevenson WG, Liotta LA, Kleiner DE Jr. Extracellular matrix 6: role of matrix metalloproteinases in tumour invasion and metastasis. FASEB J 1993; 7: 1434-1441.
4. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumour invasion. Physiol Rev 1993; 73: 161-195.
5. Höyhtyä M, Hujanen E, Turpeenniemi-Hujanen T, Thorgeirsson U, Liotta LA, Tryggvason K. Modulation of type IV collagenase activity and invasive behaviour of metastatic human melanoma (A2058) cells in vivo by monoclonal antibodies to type IV collagenase. Int J Cancer 1990; 46: 282-286.
6. Tryggvason K, Höyhtyä M, Pyke C. Type IV collagenase in invasive tumours. Breast Cancer Res Treat 1993; 24: 209-218.
7. Vassali J-D, Sappino A-D, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991; 88: 1067-1072.
8. Mueller BM. Different roles for plasminogen activators and metalloproteinases in melanoma metastasis. Curr Top Microbiol Immunol 1996; 212: 65-80.
9. Birkedal-Hansen H, Moore WGI, Bodden MK, et al. Matrix metalloproteinases. A review. Crit Rev Oral Biol Med 1993; 4: 197-250.
10. Sato K, Kida Y, Mai M, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994; 370: 61-65.
11. Cottam DW, Rees RC. Regulation of matrix metalloproteinases, their role in tumour invasion and metastasis. Int J Oncol 1993; 2: 861.
12. Albini A, Melchioti A, Santi L, Liotta LA, Brown PD, Stetler-Stevenson WG. Tumour cell invasion inhibited by TIMP-2. J Natl Cancer Inst 1991; 83: 775-779.
13. Visscher DW, Höyhtyä M, Ottosen SK, et al. Enhanced expression of tissue inhibitor of MMP-2 (TIMP-2) in the stroma of breast cancer correlates with tumour recurrence. Int J Cancer 1994; 59: 339-344.
14. Grignon DJ, Sakr W, Tith M, et al. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer. Cancer Res 1996; 56: 1654-1659.
15. Väisänen A, Tuominen H, Kallioinen M, Turpeeniemi-Hujanen T. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Pathol 1996; 180: 283-289.
16. de Vries TJ, Quax PHA, Dinjin M, et al. Plasminogen activators, their inhibitors and urokinase receptor emerge in late stages of melanocytic tumour progression. Am J Pathol 1994; 144: 70-81.
17. de Vries TJ, Mooy CM, van Balken MR, et al. Components of the plasminogen activation system in uveal melanoma - A clinico-pathological study. J Pathol 1995; 175: 59-67.
18. Cottam DW, Rennie IG, Woods K, Parsons A, Bunning RAD, Rees RC. Gelatinolytic metalloproteinase secretion patterns in ocular melanoma. Invest Ophthalmol Vis Sci 1992; 33: 1923-1927.
19. Yanoff M, Fine BS. Ocular melanocytic tumours. In: Yanott M, Fine BS, eds. Ocular Pathology. Barcelona: Mosby-Wolfe, 1996; 785-860.
20. Hsu SM, Raine L, Fanger H. The use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedure. J Histochem Cytochem 1981; 29: 557-580.
21. Väisänen A, Kallioinen M, Taskinen PJ, Höyhtyä M, Turpeenniemi-Hujanen T. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol 1998; 186: 51-58.
22. Talvensaari-Mattila A, Pääkkö P, Höyhtyä M, Blanco-Sequieros G, Turpeenniemi-Hujanen T. MMP-2 immunoreactive protein, a marker of aggressiveness in breast carcinoma. Cancer 1998; 83: 1153-1162.
23. Höyhtyä M, Turpeenniemi-Hujanen T, Stetler-Stevenson W, Krutzsch H, Tryggvason K, Liotta LA. Monoclonal antibodies to type IV collagenase recognize a protein with limited sequence homology to interstitial collagenase and stromelysin. FEBS Lett 1988; 233: 109-113.
24. Heussen C, Dowdle EB. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecylsulfate and copolymerized substrates. Ann Biochem 1980; 102: 192-202.
25. Hujanen ES, Väisänen A, Zheng A, Tryggvason K, Turpeenniemi-Hujanen T. Regulation of 72 kD and 92 kD type IV collagenase (gelatinase A and B) gene expression by interferons alpha and gamma in human melanoma. Int J Cancer 1994; 58: 582-586.
26. Nikkari ST, Höyhtyä M, Isola J, Nikkari T. Macrophages contain 92 kDa gelatinase (MMP-9) at the site of degenerated interval elastic lamina in temporal arteritis. Am J Pathol 1996; 149: 1427-1433.
27. Höyhtyä M, Fridman M, Komarek D, et al. Immunohistochemical localization of matrix metalloproteinase-2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. Int J Cancer 1994; 56: 500-505.
28. Hujanen ES, Turpeenniemi-Hujanen T. Recombinant interferon alpha and gamma modulate the invasive potential of human melanoma in vitro. Int J Cancer 1991; 47: 576-581.
29. Tripathi BJ, Park JK, Tripathi RC. Extracellular release of tissue plasminogen activator is increased with the phagocytic activity of the retinal pigment epithelium. Invest Ophthalmol Vis Sci 1989; 30: 2470-2473.
30. Smine A, Plantner JJ. Membrane type-1 matrix metalloproteinase in human ocular tissues. Curr Eye Res 1997; 16: 925-929.
31. Padgett LC, Lui G-M, Werb Z, LaVail MM. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 in the retinal pigment epithelium and interphotoreceptor matrix: vectorial secretion and regulation. Exp Eye Res 1997; 64: 927-938.